ProQR Therapeutics (PRQR) Total Debt (2013 - 2026)
ProQR Therapeutics (PRQR) posted Total Debt of $5.8 million for Q1 2026, up 2.08% sequentially from $5.7 million in Q4 2025, and up 18.23% YoY from $4.9 million in Q1 2025.
ProQR Therapeutics (PRQR) Total Debt (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Total Debt for 14 years, with the latest figure at $5.8 million in Q1 2026.
- Quarterly Total Debt rose 18.23% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 18.23% YoY) and the FY2025 annual result came in at $5.7 million, up 15.83% from the prior year.
- Total Debt advanced to $5.8 million in Q1 2026 per PRQR's latest filing, from $5.7 million in the prior quarter.
- Over five years, Total Debt peaked at $86.1 million in Q1 2022 and troughed at $4.6 million in Q4 2023.
- A 5-year average of $15.1 million and a median of $5.7 million in 2025 frame the typical range for Total Debt.
- The sharpest annual moves came in 2022 and 2023: Total Debt surged 432462.18% in 2022, then plunged 90.34% in 2023.
- Over 5 years, Total Debt stood at $6.9 million in 2022, then sank by 33.15% to $4.6 million in 2023, then gained by 6.03% to $4.9 million in 2024, then advanced by 15.83% to $5.7 million in 2025, then advanced by 2.08% to $5.8 million in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $5.8 million, $5.7 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 5.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.79 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | 5.61 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Mar 31, 2025 | 4.90 Mn |
| Dec 31, 2024 | 4.90 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 6.29 Mn |
| Jun 30, 2023 | 7.79 Mn |
| Mar 31, 2023 | 8.38 Mn |
| Dec 31, 2022 | 6.91 Mn |
| Sep 30, 2022 | 9.62 Mn |
| Jun 30, 2022 | 80.62 Mn |
| Mar 31, 2022 | 86.12 Mn |
| Dec 31, 2021 | 50.44 Mn |
| Sep 30, 2021 | 41.31 Mn |
| Jun 30, 2021 | 40.88 Mn |